The development of Lapdap, an affordable new treatment for malaria

Winstanley, 2000, Chemotherapy for falciparum malaria: the amoury, the problems and the prospects, Parasitol Today, 16, 146, 10.1016/S0169-4758(99)01622-1 Nzila, 2000, Molecular evidence of greater selective pressure for drug resistance exerted by the long-acting antifolate Pyrimethamine/Sulfadoxine compared with the shorter-acting chlorproguanil/dapsone on Kenyan Plasmodium falciparum, J Infect Dis, 181, 2023, 10.1086/315520 Ogutu, 2000, The efficacy of pyrimethamine-sulphadoxine (Fansidar R) in the treatment of uncomplicated Plasmodium falciparum malaria in Kenyan children, Trans R Soc Trop Med Hyg, 94, 83, 10.1016/S0035-9203(00)90450-4 Nwanyanwu, 2000, Efficacy of sulphadoxine-pyrimethamine for acute uncomplicated malaria due to Plasmodium falciparum in Malawian children under five years old, Trop Med Int Health, 5, 355, 10.1046/j.1365-3156.2000.00554.x Trigg, 1997, Resistance to pyrimethamine/sulfadoxine in Plasmodium falciparum in 12 villages in north east Tanzania and a test of chlorproguanil/dapsone, Acta Tropica, 63, 185, 10.1016/S0001-706X(96)00617-1 Mutabingwa, 2001, Chlorproguanil-dapsone for treatment of drug-resistant falciparum in Tanzania, Lancet, 358, 1218, 10.1016/S0140-6736(01)06344-9 Dorsey, 2002, Sulfadoxine/pyrimethamine alone or with amodiaquine or artesunate for treatment of uncomplicated malaria: a longitudinal randomised trial, Lancet, 360, 2031, 10.1016/S0140-6736(02)12021-6 Reich, 2001, The global drug gap, Science, 287, 1979, 10.1126/science.287.5460.1979 Webber, 2001, Perspectives on stimulating industrial research and development for neglected infectious diseases, Bull World Health Organ, 79, 735 Trouiller, 2002, Drug development for neglected diseases: a deficient market and a public-health policy failure, Lancet, 359, 2188, 10.1016/S0140-6736(02)09096-7 Watkins, 1987, A preliminary pharmacokinetic study of the antimalarial drugs, proguanil and chlorproguanil, J Pharm Pharm, 39, 261, 10.1111/j.2042-7158.1987.tb06263.x Winstanley, 1997, Chlorproguanil/dapsone for uncomplicated Plasmodium falciparum malaria in young children: pharmacokinetics and therapeutic range, Trans R Soc Trop Med Hyg, 91, 322, 10.1016/S0035-9203(97)90093-6 Watkins, 1988, Chlorproguanil/dapsone for the treatment of non-severe Plasmodium falciparum malaria in Kenya: a pilot study, Trans R Soc Trop Med Hyg, 82, 398, 10.1016/0035-9203(88)90133-2 Amukoye, 1997, Chlorproguanil-dapsone: effective treatment for uncomplicated falciparum malaria, Antimicrob Agents Chemother, 41, 2261, 10.1128/AAC.41.10.2261 Blockman, 1995 Sulo, 2002, Chlorproguanil-dapsone versus sulfadoxine-pyrimethamine for sequential episodes of uncomplicated falciparum malaria in Kenya and Malawi: a randomised clinical trial, Lancet, 360, 1136, 10.1016/S0140-6736(02)11198-6 Keuter, 1990, 466 Winstanley, 1995, The in-vitro activity of novel antifolate drug combinations against Plasmodiumfalciparum and human granulocyte colony-forming-units, Antimicrob Ag Chemother, 39, 948, 10.1128/AAC.39.4.948 Watkins, 1997, The efficacy of antifolate combinations in Africa: a predictive model based on pharmacodynamic and pharmacokinetic analyses, Parasitol Today, 13, 459, 10.1016/S0169-4758(97)01124-1 Maxwell, 1999, Comparison of bednets impregnated with different pyrethroids for their impact on mosquitoes and on re-infection with malaria after clearance of pre-existing infections with chlorproguanil-dapsone, Trans R Soc Trop Med Hyg, 93, 4, 10.1016/S0035-9203(99)90158-X Kublin, 2002, Molecular markers for failure of sulphadoxine-pyrimethamine and chlorproguanil-dapsone treatment for Plasmodiumfalciparum malaria, J Infect Dis, 185, 380, 10.1086/338566 White, 1999, Antimalarial drug resistance and combination chemotherapy, Phil Trans R Soc Lond B Biol Sci, 354, 739, 10.1098/rstb.1999.0426 Anon. The pharmaceutical industry. The Economist, 1998 Feb 21; 1–15